EGFR and adenocarcinoma: Not only among invasive subtypes but among all the LUAD subtypes, lepidic adenocarcinoma subtype (LPA) had the most EGFR mutations, with 78.9% (15/19) EGFR positive patients (P = 0.003, Fig 2b) with the majority being sensitizing mutations.